See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that is often used to treat infections caused by bacteria that have developed resistance to common antibiotics [1]. According to the drug's manufacturer, tigecycline is active against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria, including many that are resistant to other antibiotics [2].

One study published in the journal Diagnostic Microbiology and Infectious Disease found that tigecycline was effective against a number of bacteria that are resistant to common antibiotics [3]. The study tested the susceptibility of various bacteria to tigecycline and other antibiotics, and found that tigecycline was active against many strains of bacteria that were resistant to other antibiotics.

According to the study, tigecycline was particularly effective against Acinetobacter baumannii, a type of bacteria that is often resistant to multiple antibiotics [3]. The study found that tigecycline was active against 98.5% of A. baumannii strains tested, including many that were resistant to other antibiotics.

Other bacteria that the study found to be susceptible to tigecycline include Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus [3]. The study found that tigecycline was active against 96.2% of K. pneumoniae strains, 95.5% of E. coli strains, and 97.6% of S. aureus strains tested.

It is important to note that while tigecycline may be effective against bacteria that are resistant to other antibiotics, it is not a first-line treatment for most infections [1]. The drug's manufacturer recommends that tigecycline be used only when other antibiotics are not appropriate or when the bacteria causing the infection are known to be resistant to other antibiotics [2].

In summary, tigecycline is a broad-spectrum antibiotic that is effective against many bacteria that are resistant to common antibiotics. According to studies, tigecycline is particularly effective against Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus that are resistant to other antibiotics. However, tigecycline should only be used when other antibiotics are not appropriate or when the bacteria causing the infection are known to be resistant to other antibiotics.

Sources:

* [1] Tigecycline (Tygacil) [Internet]. Drugs.com. 2021 [cited 2023 Feb 10]. Available from: <https://www.drugs.com/tygacil.html>.
* [2] Tygacil (tigecycline) for injection, for intravenous use [Internet]. Pfizer Laboratories Div Pfizer Inc. 2021 [cited 2023 Feb 10]. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013s014lbl.pdf>.
* [3] Sader HS, Farrell DJ. In vitro activities of tigecycline and comparator agents against clinical isolates from patients with skin and skin structure infections or intra-abdominal infections in the United States, Canada, and Europe. Diagn Microbiol Infect Dis. 2005;52(2):117-123. doi:10.1016/j.diagmicrobio.2005.02.011.